Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 43

TitleTypeExpected publication date
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Technology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110Technology appraisal guidanceTBC
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256Technology appraisal guidanceTBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Technology appraisal guidanceTBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All